Novo’s Next-Generation Obesity Shot Falls Short of Lilly Rival - Bloomberg
AI Summary1 min read
TL;DR
Novo Nordisk's new obesity drug CagriSema underperformed against Eli Lilly's Zepbound in a trial, causing Novo's stock to drop 15%.
Tags
Novo Nordiskobesity drugEli LillyCagriSemaZepbound
- Novo’s Next-Generation Obesity Shot Falls Short of Lilly Rival Bloomberg
- Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial CNBC
- Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial Reuters
- Novo Nordisk pitted a new weight-loss drug against Eli Lilly’s — and lost MarketWatch
- Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price Fierce Biotech